Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  136k   773   188

201.45
-0.90 (-0.44%)
NSE: 29 Mar 4:00 PM

Price Summary

Today's High

₹ 204

Today's Low

₹ 199.65

52 Week High

₹ 387.8

52 Week Low

₹ 191.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

24186.09 Cr.

Enterprise Value

23572.69 Cr.

No. of Shares

120.06 Cr.

P/E

22.48

P/B

2.67

Face Value

₹ 5

Div. Yield

0.25 %

Book Value (TTM)

₹  75.4

CASH

689.3 Cr.

DEBT

75.9 Cr.

Promoter Holding

60.64 %

EPS (TTM)

₹  8.96

Sales Growth

-14.31%

ROE

1.09 %

ROCE

1.74%

Profit Growth

-69.3 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Index Presence

The company is present in 25 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-14.31%
3 Year-15.62%
5 Year-7.65%

Profit Growth

1 Year-69.3%
3 Year-44.09%
5 Year-30.19%

ROE%

1 Year1.09%
3 Year3.59%
5 Year4.31%

ROCE %

1 Year1.74%
3 Year4.62%
5 Year5.26%

Debt/Equity

0.0095

Price to Cash Flow

508.11

Interest Cover Ratio

350.25

CFO/PAT (5 Yr. Avg.)

0.958672837494296

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 60.64 0
Sep 2022 60.64 0
Jun 2022 60.64 0
Mar 2022 60.64 0
Dec 2021 60.64 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 350.25.
  • The company has an efficient Cash Conversion Cycle of 69.204898901722 days.
  • Company has a healthy liquidity position with current ratio of 4.06532408190895.
  • The company has a high promoter holding of 60.64%.

 Limitations

  • The company has shown a poor profit growth of -44.0920549392726% for the Past 3 years.
  • The company has shown a poor revenue growth of -15.6207955956801% for the Past 3 years.
  • Company has a poor ROE of 3.59372322597147% over the past 3 years.
  • Company has a poor ROCE of 4.61911096728709% over the past 3 years
  • The company is trading at a high PE of 22.48.
  • The company is trading at a high EV/EBITDA of 65.662.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 473 517.7 441.7 489.5 555
Total Expenditure 438.7 491.2 439.1 461.7 517.9
Operating Profit 34.3 26.5 2.6 27.8 37.1
Other Income 36.7 60.8 48.6 98.9 59.9
Interest 0.1 0 0.1 0 21.4
Depreciation 27.6 28.1 28.6 29.8 29.1
Exceptional Items 0 0 0 1009.2 0
Profit Before Tax 43.3 59.2 22.5 1106.1 46.5
Tax 17.8 21.1 7.6 118.6 11.3
Profit After Tax 25.5 38.1 14.9 987.5 35.2
Adjusted EPS (Rs) 0.21 0.32 0.12 8.23 0.29

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 2419.2 2893.3 1988.4 2028.4 1738.2
Total Expenditure 2101 2554.3 1706.5 1717.2 1677.1
Operating Profit 318.2 339 281.9 311.2 61.1
Other Income 124.7 109.3 205.8 151.5 187.2
Interest 1 2.6 1.2 0.4 0.4
Depreciation 136.1 92.3 98 103.5 108.2
Exceptional Items 0 198.7 159.7 0 0
Profit Before Tax 305.8 552.1 548.2 358.8 139.7
Tax 67.3 59.4 111.9 78.3 53.6
Net Profit 238.5 492.7 440.9 280.5 86.1
Adjusted EPS (Rs.) 1.99 4.11 3.64 2.34 0.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 300 300 600 600 600.3
Total Reserves 6438.6 6815.4 6937.3 7307.1 7492.6
Borrowings 67.2 1.4 0.7 0 75.9
Other N/C liabilities -12.7 -71.6 -134.7 -30 -10.7
Current liabilities 831.6 993.3 728 550.2 590.9
Total Liabilities 7624.7 8038.5 8131.3 8427.3 8749
Assets
Net Block 858.8 1059.2 720.7 728.6 804.7
Capital WIP 318.5 254.5 151.9 164.6 270.3
Intangible WIP 0 0 0 14.6 14.6
Investments 3745.2 3979.7 4814 5073.4 5017.8
Loans & Advances 558.7 180.7 280.9 150.5 154.2
Other N/C Assets 85.8 53 80.1 126.3 85.2
Current Assets 2057.7 2511.4 2083.7 2169.3 2402.2
Total Assets 7624.7 8038.5 8131.3 8427.3 8749
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 305.8 552.1 559.9 358.8 139.7
Adjustment 64.9 -111.8 -68.1 117.8 108.3
Changes in Assets & Liabilities 72.2 -193.9 -14 156 -172
Tax Paid -87.7 -136.9 -90.7 -61.3 -28.4
Operating Cash Flow 355.2 109.5 387.1 571.3 47.6
Investing Cash Flow -553.1 315.3 -188.9 -720.6 -302.1
Financing Cash Flow -54.6 -208.2 -128.9 27.8 112
Net Cash Flow -252.5 216.6 69.3 -121.5 -142.5

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 60.64 60.64 60.64 60.64 60.64
kiran mazumdar shaw 39.62 39.62 39.62 39.62 39.62
glentec internatio... 19.76 19.76 19.76 19.76 19.76
john mccallum mars... 0.70 0.70 0.70 0.70 0.70
ravi rasendra mazu... 0.40 0.40 0.40 0.40 0.40
yamini r mazumdar 0.11 0.11 0.11 0.11 0.11
dev mazumdar 0.04 0.04 0.04 0.04 0.04
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 39.36 39.36 39.36 39.36 39.36
lici ulip-growth f... - - - 4.25 4.25
life insurance cor... - 4.24 4.24 - -
life insurance cor... 4.11 - - - -
ahan- i ltd 1.66 1.66 2.33 2.33 2.33
life insurance cor... - - - - -
arohi emerging asi... - - 1.56 1.56 1.56
icici prudential m... - - - - -
icici prudential f... - - - - -
reliance capital t... - - - - -
arun suresh chanda... 1.10 1.10 1.10 1.10 1.10
aditya birla sun l... - - - - -
jupiter india fund - - - - -
icici prudential r... - - - - -
aditya birla sun l... - - - - -
reliance capital t... - - - - -
mirae asset large ... - - - - -
societe generale - - - - -
qualified institut... 0.61 - - - -
beneficial holding... 0.46 0.46 0.46 0.46 0.46
iepf 0.01 0.01 0.01 0.01 0.01

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Biocon’s arm wins ‘Bioprocessing Excellence in South Asia’ Award28 Mar 2023, 4:58PM Biocon informs about disclosure20 Mar 2023, 1:42PM Biocon informs about analyst meet 16 Mar 2023, 4:34PM Biocon informs about analyst meet3 Mar 2023, 1:09PM Integrated Core Strategies (Asia) buys shares of Biocon for Rs 185 crore1 Mar 2023, 3:29PM Biocon informs about analyst meet 23 Feb 2023, 2:40PM Biocon redeems commercial papers of Rs 2,250 crore23 Feb 2023, 11:19AM Biocon informs about transcript of earnings call 22 Feb 2023, 12:13PM Biocon raises Rs 1070 crore through NCDs22 Feb 2023, 11:37AM Biocon recalls 3,665 bottles of Posaconazole Delayed-Release Tablets in US market20 Feb 2023, 2:58PM Biocon - Quaterly Results14 Feb 2023, 7:18PM Biocon - Quaterly Results14 Feb 2023, 7:18PM Biocon informs about credit rating8 Feb 2023, 5:12PM Biocon offloads 10% stake in Syngene International2 Feb 2023, 9:59AM Biocon’s CSR arm wins IHW Gold Award 24 Jan 2023, 2:09PM Biocon informs about press release24 Jan 2023, 10:48AM Biocon informs about company statement7 Jan 2023, 2:37PM Biocon informs about press release22 Dec 2022, 4:58PM Biocon’s arm recognized as company with great managers at GMA 202222 Dec 2022, 4:28PM Biocon informs about analyst meet 21 Dec 2022, 12:17PM Biocon informs about analyst meet16 Dec 2022, 4:46PM Biocon starts clinical study of Itolizumab for Ulcerative Colitis in India15 Dec 2022, 12:07PM Biocon informs about analyst meet 1 Dec 2022, 4:35PM Biocon informs about analyst meet1 Dec 2022, 12:34PM Biocon’s arm completes acquisition of Viatris’ global biosimilars business30 Nov 2022, 10:21AM Biocon raises Rs 2,250 crore through Commercial Papers24 Nov 2022, 10:29AM Biocon signs semi-exclusive partnership agreement with Zentiva24 Nov 2022, 9:24AM Biocon’s arm executes debt facility agreement 22 Nov 2022, 4:22PM Biocon reports 49% fall in Q2 consolidated net profit15 Nov 2022, 2:22PM Biocon gets nod to raise $250 million via NCDs 15 Nov 2022, 9:23AM Biocon - Quaterly Results14 Nov 2022, 8:21PM Biocon - Quaterly Results14 Nov 2022, 8:21PM Biocon’s arm featured on the prestigious Asia IP ELITE list for 2022 by lAM11 Nov 2022, 12:46PM Biocon named among Top 10 employers in global biotech, pharma and biopharma sector 31 Oct 2022, 5:46PM Biocon’s arm enters into strategic out-licensing agreement with Yoshindo 17 Oct 2022, 9:29AM Biocon informs about press release17 Oct 2022, 9:28AM Biocon informs about updates7 Oct 2022, 11:52AM EDQM conducts GMP inspection at Biocon’s Bangalore unit7 Oct 2022, 10:59AM Biocon informs about disclosure 14 Sep 2022, 12:36PM Biocon divests 5.4% stake in Syngene International7 Sep 2022, 10:11AM Biocon informs about analyst meet2 Sep 2022, 11:51AM Biocon informs about analyst meet19 Aug 2022, 12:08PM Biocon informs about updates17 Aug 2022, 12:35PM Biocon informs about press release5 Aug 2022, 1:09PM Biocon - Quaterly Results27 Jul 2022, 6:58PM Biocon - Quaterly Results27 Jul 2022, 6:58PM USFDA issues three observations to Biocon’s Telangana manufacturing plant 22 Jul 2022, 10:41AM Biocon informs about newspaper advertisement7 Jul 2022, 12:35PM Biocon’s arm gets EU GMP certification for new biologics manufacturing facility in Bengaluru6 Jul 2022, 9:20AM Biocon informs about AGM1 Jul 2022, 4:19PM

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biocon and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 47.6 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biocon has a Debt to Equity ratio of 0.0095 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biocon , the EPS growth was -69.3219251336898 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biocon has OPM of 3.51513059486826 % which is a bad sign for profitability.
     
  • ROE: Biocon have a poor ROE of 1.0896527285613 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Biocon

X